RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 129 filers reported holding RECURSION PHARMACEUTICALS IN in Q1 2022. The put-call ratio across all filers is 1.41 and the average weighting 1.8%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $161,674,096 | +1.3% | 21,556,546 | +34.6% | 0.00% | 0.0% |
Q1 2024 | $159,667,197 | +3.4% | 16,014,764 | +2.2% | 0.00% | 0.0% |
Q4 2023 | $154,458,970 | +30.2% | 15,665,210 | +1.0% | 0.00% | 0.0% |
Q3 2023 | $118,627,280 | +41.0% | 15,506,834 | +37.7% | 0.00% | +50.0% |
Q2 2023 | $84,110,946 | +15.3% | 11,259,832 | +3.0% | 0.00% | 0.0% |
Q1 2023 | $72,927,005 | -6.0% | 10,933,584 | +8.7% | 0.00% | 0.0% |
Q4 2022 | $77,542,269 | -13.0% | 10,057,363 | +20.0% | 0.00% | -33.3% |
Q3 2022 | $89,174,000 | +56.8% | 8,380,986 | +19.9% | 0.00% | +50.0% |
Q2 2022 | $56,879,000 | +20.2% | 6,987,467 | +5.7% | 0.00% | +100.0% |
Q1 2022 | $47,338,000 | -54.8% | 6,611,377 | +8.1% | 0.00% | -50.0% |
Q4 2021 | $104,731,000 | +67.8% | 6,113,873 | +125.4% | 0.00% | 0.0% |
Q3 2021 | $62,403,000 | -36.3% | 2,711,980 | +1.1% | 0.00% | 0.0% |
Q2 2021 | $97,934,000 | – | 2,683,107 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Data Collective IV GP, LLC | 5,941,120 | $45,806,035 | 48.11% |
Kinnevik AB (publ) | 7,653,061 | $59,005,100 | 33.28% |
MV Management XI, L.L.C. | 1,971,908 | $15,203,411 | 26.45% |
MIC Capital Management UK LLP | 8,451,758 | $65,163,057 | 12.86% |
ArchPoint Investors | 1,114,626 | $8,593,766 | 4.07% |
HARVARD MANAGEMENT CO INC | 1,509,254 | $11,636,348 | 1.44% |
PLATINUM INVESTMENT MANAGEMENT LTD | 2,710,339 | $20,896,714 | 0.80% |
Duquesne Family Office | 1,385,950 | $10,685,675 | 0.53% |
ALLEN OPERATIONS LLC | 217,657 | $1,678,135 | 0.45% |
Artal Group S.A. | 960,204 | $7,403 | 0.41% |